Skip to main content
ANATARA LIFESCIENCES LTD logo

ANATARA LIFESCIENCES LTD — Investor Relations & Filings

Ticker · ANR ISIN · AU000000ANR0 ASX Professional, scientific and technical activities
Open in API
Filings indexed 557 across all filing types
Latest filing 2026-04-28 Interim / Quarterly Rep…
Country AU Australia
Listing ASX ANR

About ANATARA LIFESCIENCES LTD

https://anataralifesciences.com/

Anatara Lifesciences Ltd is a life sciences company focused on the development of evidence-based solutions for gastrointestinal health in both humans and animals. The company specializes in creating non-antibiotic oral products that address gut health issues and inflammatory diseases. Its lead human health product, Gastrointestinal Re-Programming (GaRP), is a multi-component dietary supplement designed to manage symptoms of Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD) by restoring the gut lining and balancing the microbiome. In the animal health sector, the company developed Detach, a natural, non-antibiotic treatment for diarrheal disease in livestock. Anatara’s research focuses on bridging the gap between conventional medicine and natural therapies through rigorous clinical validation, targeting markets seeking sustainable alternatives to traditional antibiotics and effective management of chronic digestive conditions.

Recent filings

Filing Released Lang Actions
Quarterly Activities/Appendix 4C Cash Flow Report 9 pages 602.2KB
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "4C & Q3 FY26 Activities Report" and includes detailed quarterly updates on company activities, research progress, and financial cash flow statements. It contains a consolidated statement of cash flows for the quarter ended 31 March 2026, with specific financial data such as cash at the end of the quarter, net cash flows from operating, investing, and financing activities, and payments to related parties. The presence of actual financial data and analysis for a quarter shorter than a full fiscal year, along with operational updates, aligns with the definition of an Interim / Quarterly Report (IR). The document is not merely an announcement or a brief summary but a comprehensive quarterly report with substantive financial information and business updates.
2026-04-28 English
Appendix 4D & Half Year Report 31 December 2025 24 pages 298.4KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4D' and is for the half year ended 31 December 2025, which is a typical format for an interim financial report in Australia. It contains detailed financial statements including profit or loss, financial position, cash flows, notes, and directors' report. The document length is 15,000 characters, indicating it is a full report rather than a brief announcement. The presence of consolidated interim financial statements and detailed operational review confirms it is a comprehensive interim report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2026-02-24 English
Conversion of Performance Rights 2 pages 306.0KB
Share Issue/Capital Change Classification · 95% confidence The document is an ASX release dated 25 February 2026 from Anatara Lifesciences Ltd regarding the conversion of performance rights into ordinary shares. It includes a Cleansing Notice under section 708A(5)(e) of the Corporations Act 2001, confirming compliance with disclosure requirements related to the share issuance. The document is relatively short (4233 characters) and primarily serves as an announcement of a share conversion event and related regulatory compliance. There are no financial statements, detailed financial data, or management discussion of results. The document also references an Appendix 2A released concurrently, which is typical for share issue notifications. This fits the category of a Share Issue/Capital Change announcement rather than a full financial report or other filing types. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2026-02-24 English
Application for quotation of securities - ANR 6 pages 18.4KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX (Australian Securities Exchange) announcement used for the application for quotation of securities. It details the issuance and quotation of new securities resulting from the exercise of options or conversion of convertible securities. The document includes specifics such as the number of securities, issue date, and whether the securities are part of an employee incentive scheme. This type of announcement is related to changes in the company's capital structure, specifically the issuance and quotation of new shares. It is not a financial report, earnings release, or management discussion, but rather a formal notification of a capital change. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length and content confirm it is the announcement itself, not a brief notice or a report publication announcement.
2026-02-24 English
Company Update 3 pages 333.0KB
Regulatory Filings Classification · 95% confidence The document is an ASX release titled 'Anatara Company Update' dated 19 February 2026. It provides detailed updates on the company's Anti-Obesity Project, including pre-clinical study results, mechanism of action assays, and plans for a limited pharmacokinetic clinical study. It also discusses corporate activities, strategic directions, and future plans including potential M&A. The document is a company update focusing on ongoing research and development activities and strategic considerations rather than a formal financial report or regulatory filing. It does not contain financial statements, earnings data, or audit information. It is not a call transcript, AGM material, or voting results announcement. The content is consistent with a corporate update or business progress report typically issued as a regulatory announcement to inform investors and the market about project status and company plans. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other specific categories.
2026-02-18 English
Quarterly Activities/Appendix 4C Cash Flow Report 9 pages 509.7KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX release titled 'Anatara Lifesciences 4C & Q2 FY26 Activities Report' dated January 30, 2026. It provides a quarterly update on the company's activities, including research progress, corporate activities, and a detailed Appendix 4C cash flow report for the quarter ended December 31, 2025. The Appendix 4C is a standard quarterly cash flow report required by ASX Listing Rule 4.7B, which is a regulatory filing for entities listed on the ASX. The document includes substantive financial data such as cash flows from operating, investing, and financing activities, and commentary on capital raising and cash position. The presence of the Appendix 4C cash flow report and the quarterly activity update indicates this is an Interim / Quarterly Report. It is not merely an announcement of a report but contains actual financial statements and analysis for the quarter. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2026-01-29 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.